Search
Now showing items 11-15 of 15
Endocannabinoid system mediates the association between gut-microbial diversity and anhedonia/amotivation in a general population cohort
(2021-05)
Anhedonia and amotivation are debilitating symptoms and represent unmet therapeutic needs in a range of clinical conditions. The gut-microbiome-endocannabinoid axis might represent a potential modifiable target for ...
Violent outcomes in first-episode psychosis: A clinical cohort study
(2019-11)
Aim
Violence risk is an important part of a comprehensive clinical assessment in first‐episode psychosis. This study addresses limitations of previous violent outcome research in first‐episode psychosis, which has typically ...
The early impact of the COVID-19 pandemic on patients with severe mental illness: An interrupted time-series study in South-East England
(2022-04)
Abstract
Background. Deterioration in general population mental health since the start of the COVID-19
pandemic has been reported, but the impact of the pandemic on people with severe mental
illness (SMI) has received ...
The psychological journey of weight gain in psychosis
(2022-02)
Rapid weight gain is common with antipsychotic medication. Lost confidence, low mood and medication non-adherence often follow. Yet, the dynamic interactions between the physical and psychological consequences of weight ...
The serum metabolomic profile of a distinct, inflammatory subtype of acute psychosis
(2022-09)
A range of studies suggest that a proportion of psychosis may have an autoimmune basis, but this has not translated through into clinical practice—there is no biochemical test able to accurately identify psychosis resulting ...